Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 5/20 | 0.47 |
| ▸ | TK2 | O00142 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913275 | 1.00 | DUT (0.50) | DUTKIF11TK1TK2KDM4E | |
| SCHEMBL12268294 | 1.00 | DUT (0.50) | DUTKIF11TK1TK2KDM4E | |
| SCHEMBL5436615 | 0.83 | ALDH1A1 (0.47) | DUTKIF11TK1TK2KDM4E | |
| SCHEMBL20974784 | 0.79 | DUT (0.47) | DUTKIF11TK1TK2ALDH1A1 | |
| SCHEMBL28500553 | 0.79 | DUT (0.47) | DUTKIF11TK1TK2ALDH1A1 | |
| SCHEMBL8322266 | 0.79 | DUT (0.47) | DUTKIF11TK1TK2ALOX15 | |
| SCHEMBL8552387 | 0.79 | DUT (0.47) | DUTKIF11TK1TK2ALOX15 | |
| SCHEMBL6241174 | 0.76 | KIF11 (0.56) | DUTKIF11HRH4ALOX15ALDH1A1 | |
| SCHEMBL2856185 | 0.75 | KIF11 (0.50) | DUTKIF11TK1TK2HRH4 | |
| SCHEMBL11303069 | 0.75 | KIF11 (0.50) | DUTKIF11TK1TK2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20100075924-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-25 | — | — | US | disclosed |
| US-7601702-B2 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2009-10-13 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1701952-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066160-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| EP-0282077-B1 | Pyridyloxy derivatives | FUJIREBIO KK (JP) | 1993-11-10 | — | — | EP | disclosed |
| US-4977267-A | ANTISECRETORY AGENT | FUJIREBIO KABUSHIKI KAISHA (JP) | 1990-12-11 | — | — | US | disclosed |
| US-4912101-A | Containing a secondary amide, suflur group and a furan ring | FUJIREBIO KABUSHIKI KAISHA (JP) | 1990-03-27 | — | — | US | disclosed |
| EP-0282077-A2 | Pyridyloxy derivatives | FUJIREBIO KABUSHIKI KAISHA (JP) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300216-A1 | Dutpase Inhibitors | DUT, DHODH, POLR2H | DUT 1/4885KIF11 4014/4885TK1 277/4885 |
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | DUT 1/4885KIF11 2729/4885TK1 75/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | DUT 1/4885KIF11 2686/4885TK1 118/4885 |
| US-20100075924-A1 | DUTPASE INHIBITORS | DUT, DHODH, CCNO | DUT 1/4885KIF11 3964/4885TK1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.